AAPL297.04+0.03 (+0.01%) ▲|ABBV233.60+3.59 (+1.56%) ▲|ABT90.22+2.39 (+2.72%) ▲|ACN126.88+2.05 (+1.64%) ▲|ADBE197.77+2.87 (+1.47%) ▲|AMAT580.99-59.19 (-9.25%) ▼|AMD517.30-34.33 (-6.22%) ▼|AMGN347.52+2.80 (+0.81%) ▲|AMT178.51+2.08 (+1.18%) ▲|AMZN234.74+1.95 (+0.84%) ▲|AVGO380.92-11.22 (-2.86%) ▼|AXP337.37-0.71 (-0.21%) ▼|BA218.33-2.50 (-1.13%) ▼|BAC57.89+0.52 (+0.90%) ▲|BKNG168.67+0.90 (+0.53%) ▲|BLK1,016.29-35.45 (-3.37%) ▼|BMY55.85+1.15 (+2.10%) ▲|BNY147.50+1.06 (+0.72%) ▲|BRK-B492.96+4.27 (+0.87%) ▲|C145.34-0.34 (-0.23%) ▼|CAT985.22-37.06 (-3.63%) ▼|CL91.42+2.75 (+3.10%) ▲|CMCSA23.01+0.69 (+3.09%) ▲|COF197.35-3.35 (-1.67%) ▼|COP109.70+0.00 (+0.00%) ▲|COST958.86+7.51 (+0.79%) ▲|CRM153.84+3.72 (+2.48%) ▲|CSCO121.00-0.53 (-0.44%) ▼|CVS101.40+0.10 (+0.10%) ▲|CVX175.77+0.71 (+0.40%) ▲|DE591.40-7.20 (-1.20%) ▼|DHR178.80+0.61 (+0.34%) ▲|DIS103.66+1.21 (+1.18%) ▲|DUK125.25+1.73 (+1.40%) ▲|EMR143.58-6.63 (-4.41%) ▼|FDX321.20-7.59 (-2.31%) ▼|GD349.01+5.65 (+1.64%) ▲|GE355.79+0.67 (+0.19%) ▲|GEV1,039.82-87.78 (-7.78%) ▼|GILD125.63+0.76 (+0.61%) ▲|GM79.20-1.23 (-1.53%) ▼|GOOG346.27-2.51 (-0.72%) ▼|GOOGL346.86-2.70 (-0.77%) ▼|GS1,098.32-8.06 (-0.73%) ▼|HD325.59-1.03 (-0.32%) ▼|HON221.91-6.20 (-2.72%) ▼|IBM263.24+11.02 (+4.37%) ▲|INTC132.52-8.42 (-5.97%) ▼|INTU258.39+0.62 (+0.24%) ▲|ISRG402.25-0.70 (-0.17%) ▼|JNJ238.44+7.15 (+3.09%) ▲|JPM334.36+2.88 (+0.87%) ▲|KO80.19+0.66 (+0.83%) ▲|LIN514.63-2.08 (-0.40%) ▼|LLY1,107.53+5.45 (+0.49%) ▲|LMT501.23+7.63 (+1.55%) ▲|LOW214.15-0.25 (-0.12%) ▼|LRCX370.23-39.31 (-9.60%) ▼|MA488.29+4.20 (+0.87%) ▲|MCD271.95+1.85 (+0.68%) ▲|MDLZ61.06+1.55 (+2.60%) ▲|MDT80.48+1.21 (+1.53%) ▲|META563.77-0.08 (-0.01%) ▼|MMM162.01-1.22 (-0.74%) ▼|MO71.42+1.91 (+2.75%) ▲|MRK119.16+3.68 (+3.18%) ▲|MS226.52-0.58 (-0.25%) ▼|MSFT373.41+6.07 (+1.65%) ▲|MU1,049.14-162.24 (-13.39%) ▼|NEE86.46+0.38 (+0.44%) ▲|NFLX73.06+0.18 (+0.25%) ▲|NKE42.71-0.49 (-1.12%) ▼|NOW96.45+3.44 (+3.70%) ▲|NVDA200.95-7.70 (-3.69%) ▼|ORCL166.06-9.01 (-5.15%) ▼|PEP142.02+1.31 (+0.93%) ▲|PFE24.90-0.19 (-0.74%) ▼|PG150.97+3.29 (+2.23%) ▲|PLTR116.97-2.53 (-2.12%) ▼|PM177.44+4.27 (+2.47%) ▲|QCOM203.28-18.63 (-8.39%) ▼|RTX185.40+3.57 (+1.96%) ▲|SBUX101.08+0.93 (+0.93%) ▲|SCHW92.85+0.82 (+0.89%) ▲|SO94.82+1.39 (+1.49%) ▲|SPG216.79+2.22 (+1.03%) ▲|T22.92+0.82 (+3.69%) ▲|TMO467.35+3.34 (+0.72%) ▲|TMUS184.49+4.43 (+2.46%) ▲|TSLA381.24-23.81 (-5.88%) ▼|TXN302.71-29.58 (-8.90%) ▼|UBER69.70-1.73 (-2.42%) ▼|UNH408.04+1.36 (+0.33%) ▲|UNP259.48-0.43 (-0.17%) ▼|UPS105.98-1.27 (-1.18%) ▼|USB59.94+1.26 (+2.15%) ▲|V328.67+2.07 (+0.63%) ▲|VZ46.77+1.41 (+3.10%) ▲|WFC84.09+0.25 (+0.29%) ▲|WMT119.54+2.36 (+2.01%) ▲|XOM139.93+1.46 (+1.05%) ▲|AAPL297.04+0.03 (+0.01%) ▲|ABBV233.60+3.59 (+1.56%) ▲|ABT90.22+2.39 (+2.72%) ▲|ACN126.88+2.05 (+1.64%) ▲|ADBE197.77+2.87 (+1.47%) ▲|AMAT580.99-59.19 (-9.25%) ▼|AMD517.30-34.33 (-6.22%) ▼|AMGN347.52+2.80 (+0.81%) ▲|AMT178.51+2.08 (+1.18%) ▲|AMZN234.74+1.95 (+0.84%) ▲|AVGO380.92-11.22 (-2.86%) ▼|AXP337.37-0.71 (-0.21%) ▼|BA218.33-2.50 (-1.13%) ▼|BAC57.89+0.52 (+0.90%) ▲|BKNG168.67+0.90 (+0.53%) ▲|BLK1,016.29-35.45 (-3.37%) ▼|BMY55.85+1.15 (+2.10%) ▲|BNY147.50+1.06 (+0.72%) ▲|BRK-B492.96+4.27 (+0.87%) ▲|C145.34-0.34 (-0.23%) ▼|CAT985.22-37.06 (-3.63%) ▼|CL91.42+2.75 (+3.10%) ▲|CMCSA23.01+0.69 (+3.09%) ▲|COF197.35-3.35 (-1.67%) ▼|COP109.70+0.00 (+0.00%) ▲|COST958.86+7.51 (+0.79%) ▲|CRM153.84+3.72 (+2.48%) ▲|CSCO121.00-0.53 (-0.44%) ▼|CVS101.40+0.10 (+0.10%) ▲|CVX175.77+0.71 (+0.40%) ▲|DE591.40-7.20 (-1.20%) ▼|DHR178.80+0.61 (+0.34%) ▲|DIS103.66+1.21 (+1.18%) ▲|DUK125.25+1.73 (+1.40%) ▲|EMR143.58-6.63 (-4.41%) ▼|FDX321.20-7.59 (-2.31%) ▼|GD349.01+5.65 (+1.64%) ▲|GE355.79+0.67 (+0.19%) ▲|GEV1,039.82-87.78 (-7.78%) ▼|GILD125.63+0.76 (+0.61%) ▲|GM79.20-1.23 (-1.53%) ▼|GOOG346.27-2.51 (-0.72%) ▼|GOOGL346.86-2.70 (-0.77%) ▼|GS1,098.32-8.06 (-0.73%) ▼|HD325.59-1.03 (-0.32%) ▼|HON221.91-6.20 (-2.72%) ▼|IBM263.24+11.02 (+4.37%) ▲|INTC132.52-8.42 (-5.97%) ▼|INTU258.39+0.62 (+0.24%) ▲|ISRG402.25-0.70 (-0.17%) ▼|JNJ238.44+7.15 (+3.09%) ▲|JPM334.36+2.88 (+0.87%) ▲|KO80.19+0.66 (+0.83%) ▲|LIN514.63-2.08 (-0.40%) ▼|LLY1,107.53+5.45 (+0.49%) ▲|LMT501.23+7.63 (+1.55%) ▲|LOW214.15-0.25 (-0.12%) ▼|LRCX370.23-39.31 (-9.60%) ▼|MA488.29+4.20 (+0.87%) ▲|MCD271.95+1.85 (+0.68%) ▲|MDLZ61.06+1.55 (+2.60%) ▲|MDT80.48+1.21 (+1.53%) ▲|META563.77-0.08 (-0.01%) ▼|MMM162.01-1.22 (-0.74%) ▼|MO71.42+1.91 (+2.75%) ▲|MRK119.16+3.68 (+3.18%) ▲|MS226.52-0.58 (-0.25%) ▼|MSFT373.41+6.07 (+1.65%) ▲|MU1,049.14-162.24 (-13.39%) ▼|NEE86.46+0.38 (+0.44%) ▲|NFLX73.06+0.18 (+0.25%) ▲|NKE42.71-0.49 (-1.12%) ▼|NOW96.45+3.44 (+3.70%) ▲|NVDA200.95-7.70 (-3.69%) ▼|ORCL166.06-9.01 (-5.15%) ▼|PEP142.02+1.31 (+0.93%) ▲|PFE24.90-0.19 (-0.74%) ▼|PG150.97+3.29 (+2.23%) ▲|PLTR116.97-2.53 (-2.12%) ▼|PM177.44+4.27 (+2.47%) ▲|QCOM203.28-18.63 (-8.39%) ▼|RTX185.40+3.57 (+1.96%) ▲|SBUX101.08+0.93 (+0.93%) ▲|SCHW92.85+0.82 (+0.89%) ▲|SO94.82+1.39 (+1.49%) ▲|SPG216.79+2.22 (+1.03%) ▲|T22.92+0.82 (+3.69%) ▲|TMO467.35+3.34 (+0.72%) ▲|TMUS184.49+4.43 (+2.46%) ▲|TSLA381.24-23.81 (-5.88%) ▼|TXN302.71-29.58 (-8.90%) ▼|UBER69.70-1.73 (-2.42%) ▼|UNH408.04+1.36 (+0.33%) ▲|UNP259.48-0.43 (-0.17%) ▼|UPS105.98-1.27 (-1.18%) ▼|USB59.94+1.26 (+2.15%) ▲|V328.67+2.07 (+0.63%) ▲|VZ46.77+1.41 (+3.10%) ▲|WFC84.09+0.25 (+0.29%) ▲|WMT119.54+2.36 (+2.01%) ▲|XOM139.93+1.46 (+1.05%) ▲|
20.6 C
New York
Tuesday, June 23, 2026

Tag: European Union

newssourceFORcompanyinformationcontent1marketreleases

Mainframe Modernization Services Market to Reach USD 76.16 Billion by 2032, Growing at a CAGR of 15.1%: Credence Research

PUNE, India, June 18, 2025 /PRNewswire/ -- According to a recent market analysis published by Credence Research, the global Mainframe Modernization Services Market is set...

Green Hydrogen Market Size to Surge to $71.31 Billion by 2031, Fueled by 37.8% CAGR | The Insight Partners

NEW YORK, June 18, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global green hydrogen market is observing significant...

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich ataxia (FA) between the ages of 2 to <16. Both non-ambulatory and ambulatory participants may qualify for the study. Participants will be randomized 2:1 to receive omaveloxolone or placebo once a day for 52 weeks before having the opportunity to move into the open-label extension (OLE). Currently, omaveloxolone is commercialized under the brand name SKYCLARYS® in over 40 countries, including in the U.S. and the European Union, and is the only approved product for FA in adults and adolescents aged 16 years and older.

DNS4EU Goes Live, Confirming Strength of Brno’s Cybersecurity Ecosystem, Says Innovation Agency JIC

BRNO, Czech Republic, June 18, 2025 /PRNewswire/ -- The European Union's vision of digital sovereignty enters a new phase with the launch of DNS4EU, a...

A Charming Taste of Europe, Delivered to Dad: Celebrate Father’s Day in Canada with Wine & Kiwi Gift Inspiration

The Charming Taste of Europe campaign showcases the excellence of EU wine and fruit producers with a refined gift idea for Canadian dads TORONTO, June...

“The Charming Taste of Europe” Returns to the U.S. in 2025 with Events Across the Country

A multi-city tour featuring masterclasses, B2B meetings, and promotional lunches highlights the richness and diversity of Abruzzo's winemaking tradition. NEW YORK, June 17, 2025 /PRNewswire/...

ARKO successfully co-hosts the 10th World Summit on Arts and Culture

Cultural and Creative Sectors exploring the way forward in the age of AI and climate crisis and ascertaining its role in society SEOUL, South Korea,...

U.S. Food and Drug Administration Approves CSL’s ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All...

ANDEMBRY inhibits the top of the HAE cascade by targeting factor XIIa and provides sustained protection from attacksOnce-monthly dosing reduced HAE attacks by a...

“Taste the Difference” Marks a Successful Second Year of Campaign with Impactful Activities Across the U.S. Wine Trade

Exclusive trade events in Chicago and New York spotlighted premium European wines from Italy and Spain, boosting U.S. awareness of PDO and PGI European labels...

GLOBAL MANCOZEB SUMMIT: ADDRESSING ITS CRUCIAL ROLE IN CROP PROTECTION AHEAD OF EU COURT HEARING

LONDON, June 16, 2025 /PRNewswire/ -- UPL Corporation Ltd. (UPL Corp) - part of UPL Group Company (NSE: UPL) & (BSE: 512070) (LSE: UPL), a...

Investigational combination of first-in-class bispecific antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary...

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA1 

Elanco Receives Positive Opinion on Zenrelia (ilunocitinib) from EU’s Committee for Veterinary Medicinal Products (CVMP)

Company expects approval and product supply in market before the end of third quarter GREENFIELD, Ind., June 12, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:...

Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions

SINGAPORE, June 12, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the expansion of its existing supply and distribution agreement...

Aegon Annual General Meeting approves all resolutions

Amsterdam, June 12, 2025 - Aegon Ltd.'s Annual General Meeting of Shareholders (AGM) today approved all resolutions on the agenda. This included the final dividend for 2024 of EUR 0.19 per common share, bringing Aegon’s total dividend for 2024 to EUR 0.35 per common share. The meeting also approved all proposed appointments to the Board of Directors, including the reappointment of three existing members and the election of three new members.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsEuropean Union

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers